Search the Newsreel

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

Cal-Maine Foods (CALM) sees American Century, Stowers report 5.3% stake

American Century entities and the Stowers Institute for Medical Research have reported beneficial ownership of over 5% of Cal-Maine Foods' common stock through a Schedule 13G filing. American Century ETF Trust holds 5.1% of common stock, while American Century Investment Management, American Century Companies, …

Kestra Medical Technologies (KMTS) Nears Its Fair Value, Is The Stock Already Fully Valued?

Kestra Medical Technologies (KMTS) has seen recent positive share price momentum, with its stock closing at US$27.74. While a common narrative suggests the stock is undervalued with a fair value of $28 based on ambitious growth assumptions, other metrics like the P/S ratio indicate …

Worker injured in industrial accident at Westlake plant in Calvert City

A contractor's employee was hospitalized after an industrial accident at the Westlake Corporation chemical plant in Calvert City, Kentucky. The worker was injured on a Monday and received immediate care from plant emergency responders before being taken to the hospital. Westlake Corporation has halted …

Namibia Critical Metals Stock Falls 6.82%: Why TSXV:NMI Is in Focus as Lofdal Rare Earths Enters a Critical Development Phase

Calian Group Stock in Focus: Defence, Space, AI and Cybersecurity Growth Drive the 2026 Investment Story

U.S. Physical Therapy (NYSE:USPH) Trading Down 4.8% - Here's Why

Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake

Brandes Investment Partners has filed an amended Schedule 13G, disclosing a 14.92% passive ownership stake in Utah Medical Products Inc., totaling 475,158 common shares. These shares are held across mutual funds and other accounts advised by Brandes, with the Brandes Small Cap Value Fund …

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Callaway Golf (CALY) Stock May Offer Cash Flow Value As Earnings Look Rich

VerticalScope Q2 Earnings Call Highlights

Key Points Interested in VerticalScope Holdings Inc.? Here are five stocks we like better. Q2 revenue fell 5% year over year to $13.8 million, but rose 20% sequentially, while adjusted EBITDA increased 4% to $4.5 million and margin expanded to 32%. Net loss narrowed …

ETON Stock Soars After Huge Earnings Beat And Guidance Hike

Eton Pharmaceuticals (ETON) stock surged by over 40% after reporting Q2 revenue of $37.6 million, nearly double year-over-year and significantly beating consensus estimates, with adjusted EPS of $0.43. Management raised its 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at …

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Eton Pharmaceuticals Stock Jumps 38% as Guidance Reset Tests Valuation

All You Need to Know About Air Products and Chemicals (APD) Rating Upgrade to Buy

Investors might want to bet on Air Products and Chemicals (APD), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting …

Onward Medical N.V.: Graphique de cours statique | ONWD | NL0015000HT4

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Aquamarine Financial (Cayman) Ltd has reported a beneficial ownership of 2,512,175 shares in Oramed Pharmaceuticals Inc., which constitutes 6.04% of the common stock as of June 30, 2026. The filing, an amended Schedule 13G/A, indicates that Aquamarine holds sole voting and sole dispositive power …

Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy?

Alpha Tau Medical (DRTS) reported a significant widening of its net loss to US$68.75 million in the first half of 2026, up from US$18.81 million a year prior, leading to increased concerns about its funding risk. Despite the company's focus on clinical progress for …

ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256

Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and …

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

FORA: Sequential revenue growth and margin expansion driven by AI and disciplined cost control

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …

NRx Pharmaceuticals nears FDA approval milestone amid expected quarterly loss and low revenue.

NRx Pharmaceuticals is anticipating a quarterly loss of $0.09 per share and revenue of $1.33 million, despite financial challenges. The company has made significant progress towards FDA approval for its preservative-free ketamine, with major regulatory risks addressed. NRx will discuss these developments and commercialization …

Solas Capital discloses 9.99% Modular Medical (MODD) position via stock and warrants

Solas Capital Management, LLC and Frederick Tucker Golden have reported an amended beneficial ownership of 9.99% in Modular Medical, Inc. (MODD). This stake comprises 552,171 shares, including common stock and shares issuable upon warrant exercise, with shared voting and dispositive power. The filing details …

Shanghai HeartCare Seeks Shareholder Approval for Sci-Tech Board A-Share Issuance

Shanghai HeartCare Plans A Share Issue and Sci-Tech Board Listing

Earnings call transcript: VerticalScope posts Q2 2026 EPS beat as shares jump 12.5%

Amylyx Pharmaceuticals (AMLX) Is Down 7.1% After Wider Q2 Loss And Avexitide Phase III Update

Amylyx Pharmaceuticals reported a wider Q2 2026 net loss of US$43.42 million, though the loss per share improved. The company is advancing towards a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia, with potential commercialization targeted for 2027 if approved. This upcoming …

Zscaler (ZS) Stock May Trade Below Fair Value As Gartner Recognition Lands

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Zscaler's share price has delivered a 38.2% gain over the past three years, while its current checks show a mixed picture on value and an …

ICU Medical (ICUI) Insider Sells 5,417 Shares: VP, GM-Infusion Capital Daniel Woolson Reduces Stake

Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc (ICUI), sold 5,417 shares of the company on August 13, 2026, bringing his total ownership to 17,062 shares. This transaction is part of a trend where insiders at ICU Medical have generally been selling more …

Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering

Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …